## Drug Summary
Mexiletine is an antiarrhythmic agent primarily prescribed for the management of ventricular arrhythmias, such as ventricular tachycardia, and for the prevention of ventricular fibrillation. Pharmaceutically akin to lidocaine but distinct due to its oral activity, Mexiletine is known for its rapid onset and brief duration of action which is most effective at higher heart rates. Acts to modulate cardiac function by shortening the action potential duration and reducing the effective refractory period in heart muscle cells. Mexiletine has a pharmacokinetic profile characterized by high oral bioavailability (approx. 90%) and is predominantly metabolized in the liver, majorly via CYP2D6 and to a lesser extent by CYP1A2.

## Drug Targets, Enzymes, Transporters, and Carriers
Mexiletine’s primary target is the SCN5A gene product, the sodium channel protein type 5 subunit alpha, which is essential for the proper electrical functioning of cardiac cells. The drug inhibits these sodium channels, decreasing their ability to initiate and propagate electrical impulses, thereby exerting its antiarrhythmic effects. It is metabolized extensively in the liver primarily by CYP2D6, with additional involvement from CYP1A2, CYP2B6, CYP2E1, and CYP3A4. These enzymes are responsible for its hepatic biotransformation and significantly influence its pharmacokinetic behavior. There is no specific information presented regarding transporters or carriers. 

## Pharmacogenetics
Genetic variability in CYP2D6, the key enzyme responsible for Mexiletine’s metabolism, plays a crucial role in the drug's pharmacogenetics. Individuals with different CYP2D6 genotypes can experience varying levels of enzyme activity ranging from poor to ultrarapid metabolism, affecting both the efficacy and toxicity of Mexiletine. Specifically, poor metabolizers may have increased drug exposure leading to higher risks of toxicity, whereas ultrarapid metabolizers might have reduced drug levels, potentially leading to therapeutic failure. Genetic testing may provide valuable insights into CYP2D6 activity before initiating Mexiletine therapy to adjust doses appropriately. Although no specific genomic data is available from the provided summary, the involvement of the SCN5A target also suggests potential genetic associations that may influence drug response, given the critical role of this channel in cardiac electrophysiology. However, specific pharmacogenetic guidelines for SCN5A concerning Mexiletine treatment have yet to be established and would require further clinical evidence.